Teva Pharmaceutical Industries Limited Stock News

Teva has faced scandal after scandal which soured investors and the general public alike. Even though I think the $40.5 billion Actavis acquisition was a good move, it leveraged Teva to uncomfortable

Riding the Oracle of Omaha's coattails has historically been a smart move for investors.

The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.

The FDA has accepted Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.  TV-46000/mdc-IRM is a risperid

PARSIPPANY, N.J., TEL AVIV & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced toda

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in

Retailers are on deck to report earnings this week, but some macro headwinds could create uncertainty for the group.

Why Teva Pharmaceuticals Has Two A-Products In The Bag

Teva is one of the largest pharmaceutical companies in the world and the second largest generic medicine company (after Viatris) in terms of revenue.

TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view.

Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q2 2021 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) Q2 sales reached $3.9 billion, increasing 1% Y/Y or decreasing 2% in local currency terms, missing the consensus of $4.04 billion. The decrease was ma

Teva Pharmaceutical Industries Ltd.'s shares slid 2.5% in premarket trade Wednesday, after the Israeli generics maker missed revenue estimates for the second quarter and lowered guidance, citing the c

Shares of Teva Pharmaceutical Indus (NYSE:TEVA) fell 2.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 7.27% year over year to $0.59, whi

We believe that Teva Pharmaceutical stock is a good buying opportunity at the present time. TEVA stock trades near $10 currently and it is, in fact, down 28% from its pre-Covid high of around $13 in F